Do analysts prefer STVN or PSNL?

Personalis has a consensus target price of $14.54, suggesting a potential downside of 15.49%. Given Personalis' higher probable upside, analysts clearly believe Personalis is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 Personalis 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has better earnings and valuation, STVN or PSNL?

Stevanato Group has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stevanato Group €1.34B 4.62 €158.21M €0.56 36.52 Personalis $69.65M 25.86 -$81.27M -$1.09 N/A

Does the media refer more to STVN or PSNL?

In the previous week, Stevanato Group had 2 more articles in the media than Personalis. MarketBeat recorded 7 mentions for Stevanato Group and 5 mentions for Personalis. Stevanato Group's average media sentiment score of 1.14 beat Personalis' score of 0.94 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, SHC or PSNL?

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sotera Health $1.16B 4.64 $77.94M $0.57 33.16 Personalis $69.65M 25.86 -$81.27M -$1.09 N/A

Is SHC or PSNL more profitable?

Sotera Health has a net margin of 13.44% compared to Personalis' net margin of -153.84%. Sotera Health's return on equity of 40.12% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 13.44% 40.12% 7.55% Personalis -153.84% -46.47% -35.30%

Does the media refer more to SHC or PSNL?

In the previous week, Sotera Health had 3 more articles in the media than Personalis. MarketBeat recorded 8 mentions for Sotera Health and 5 mentions for Personalis. Sotera Health's average media sentiment score of 1.33 beat Personalis' score of 0.94 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PSNL or ADPT?

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Personalis. MarketBeat recorded 9 mentions for Adaptive Biotechnologies and 5 mentions for Personalis. Adaptive Biotechnologies' average media sentiment score of 1.49 beat Personalis' score of 0.94 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALMR or PSNL?

In the previous week, Personalis had 3 more articles in the media than Alamar Biosciences. MarketBeat recorded 5 mentions for Personalis and 2 mentions for Alamar Biosciences. Personalis' average media sentiment score of 0.94 beat Alamar Biosciences' score of 0.88 indicating that Personalis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PSNL or MRVI?

In the previous week, Personalis had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 5 mentions for Personalis and 4 mentions for Maravai LifeSciences. Personalis' average media sentiment score of 0.94 beat Maravai LifeSciences' score of 0.79 indicating that Personalis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Personalis (PSNL) Competitors

$17.20 +0.37 (+2.20%)

As of 04:00 PM Eastern

Compare

PSNL vs. STVN, SHC, ADPT, ALMR, and MRVI

Should you buy Personalis stock or one of its competitors? Personalis's main competitors and comparable companies include Stevanato Group (STVN), Sotera Health (SHC), Adaptive Biotechnologies (ADPT), Alamar Biosciences (ALMR), and Maravai LifeSciences (MRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Personalis compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Personalis (NASDAQ:PSNL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Stevanato Group has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Personalis has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

Stevanato Group has a net margin of 10.99% compared to Personalis' net margin of -153.84%. Stevanato Group's return on equity of 10.43% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	10.99%	10.43%	6.16%
Personalis	-153.84%	-46.47%	-35.30%

In the previous week, Stevanato Group had 2 more articles in the media than Personalis. MarketBeat recorded 7 mentions for Stevanato Group and 5 mentions for Personalis. Stevanato Group's average media sentiment score of 1.14 beat Personalis' score of 0.94 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stevanato Group has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.62	€158.21M	€0.56	36.52
Personalis	$69.65M	25.86	-$81.27M	-$1.09	N/A

Personalis has a consensus target price of $14.54, suggesting a potential downside of 15.49%. Given Personalis' higher probable upside, analysts clearly believe Personalis is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Personalis	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

61.9% of Personalis shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 4.2% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Stevanato Group beats Personalis on 11 of the 17 factors compared between the two stocks.

How does Personalis compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Personalis (NASDAQ:PSNL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Sotera Health has a net margin of 13.44% compared to Personalis' net margin of -153.84%. Sotera Health's return on equity of 40.12% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	13.44%	40.12%	7.55%
Personalis	-153.84%	-46.47%	-35.30%

In the previous week, Sotera Health had 3 more articles in the media than Personalis. MarketBeat recorded 8 mentions for Sotera Health and 5 mentions for Personalis. Sotera Health's average media sentiment score of 1.33 beat Personalis' score of 0.94 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sotera Health has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Personalis has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

Sotera Health presently has a consensus target price of $21.50, suggesting a potential upside of 13.76%. Personalis has a consensus target price of $14.54, suggesting a potential downside of 15.49%. Given Sotera Health's stronger consensus rating and higher probable upside, equities research analysts clearly believe Sotera Health is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Personalis	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.64	$77.94M	$0.57	33.16
Personalis	$69.65M	25.86	-$81.27M	-$1.09	N/A

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 15.4% of Sotera Health shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Sotera Health beats Personalis on 14 of the 16 factors compared between the two stocks.

How does Personalis compare to Adaptive Biotechnologies?

Personalis (NASDAQ:PSNL) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Personalis has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Personalis. MarketBeat recorded 9 mentions for Adaptive Biotechnologies and 5 mentions for Personalis. Adaptive Biotechnologies' average media sentiment score of 1.49 beat Personalis' score of 0.94 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adaptive Biotechnologies has a net margin of -20.73% compared to Personalis' net margin of -153.84%. Adaptive Biotechnologies' return on equity of -36.81% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

61.9% of Personalis shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 4.2% of Personalis shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Adaptive Biotechnologies has higher revenue and earnings than Personalis. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	25.86	-$81.27M	-$1.09	N/A
Adaptive Biotechnologies	$276.98M	13.99	-$59.50M	-$0.41	N/A

Personalis presently has a consensus target price of $14.54, suggesting a potential downside of 15.49%. Adaptive Biotechnologies has a consensus target price of $24.42, suggesting a potential upside of 0.56%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Adaptive Biotechnologies beats Personalis on 13 of the 16 factors compared between the two stocks.

How does Personalis compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Personalis (NASDAQ:PSNL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

Alamar Biosciences has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Alamar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	28.80	-$29.82M	-$1.96	N/A
Personalis	$69.65M	25.86	-$81.27M	-$1.09	N/A

61.9% of Personalis shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Personalis had 3 more articles in the media than Alamar Biosciences. MarketBeat recorded 5 mentions for Personalis and 2 mentions for Alamar Biosciences. Personalis' average media sentiment score of 0.94 beat Alamar Biosciences' score of 0.88 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alamar Biosciences has a net margin of 0.00% compared to Personalis' net margin of -153.84%. Alamar Biosciences' return on equity of 0.00% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Personalis	-153.84%	-46.47%	-35.30%

Alamar Biosciences presently has a consensus price target of $31.80, indicating a potential upside of 3.25%. Personalis has a consensus price target of $14.54, indicating a potential downside of 15.49%. Given Alamar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Alamar Biosciences is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Personalis	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Alamar Biosciences beats Personalis on 9 of the 14 factors compared between the two stocks.

How does Personalis compare to Maravai LifeSciences?

Personalis (NASDAQ:PSNL) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Personalis has higher earnings, but lower revenue than Maravai LifeSciences. Personalis is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	25.86	-$81.27M	-$1.09	N/A
Maravai LifeSciences	$185.74M	10.23	-$130.77M	-$0.52	N/A

Personalis has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

In the previous week, Personalis had 1 more articles in the media than Maravai LifeSciences. MarketBeat recorded 5 mentions for Personalis and 4 mentions for Maravai LifeSciences. Personalis' average media sentiment score of 0.94 beat Maravai LifeSciences' score of 0.79 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maravai LifeSciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Maravai LifeSciences has a net margin of -37.07% compared to Personalis' net margin of -153.84%. Maravai LifeSciences' return on equity of -15.70% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Personalis currently has a consensus price target of $14.54, indicating a potential downside of 15.49%. Maravai LifeSciences has a consensus price target of $6.25, indicating a potential downside of 14.62%. Given Maravai LifeSciences' higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

61.9% of Personalis shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 4.2% of Personalis shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Personalis beats Maravai LifeSciences on 9 of the 16 factors compared between the two stocks.

Get Personalis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSNL vs. The Competition

Export

Metric	Personalis	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.80B	$9.93B	$7.17B	$12.88B
Dividend Yield	N/A	1.46%	2.53%	8.57%
P/E Ratio	-15.78	65.01	272.99	25.40
Price / Sales	25.86	111.65	612.73	97.75
Price / Cash	N/A	26.86	77.82	52.27
Price / Book	7.64	35.98	12.85	6.17
Net Income	-$81.27M	$56.67B	$3.47B	$349.50M
7 Day Performance	0.76%	-0.83%	1.24%	-0.05%
1 Month Performance	27.22%	4.54%	5.81%	0.80%
1 Year Performance	237.92%	26.48%	25.75%	15.62%

Personalis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSNL Personalis	1.902 of 5 stars	$17.20 +2.2%	$14.54 -15.5%	+247.0%	$1.80B	$69.65M	N/A	400
STVN Stevanato Group	3.0313 of 5 stars	€21.43 flat	N/A	-12.1%	€6.49B	€1.34B	38.27	6,010	Positive News
SHC Sotera Health	4.0685 of 5 stars	$18.90 -1.9%	$21.50 +13.8%	+19.1%	$5.50B	$1.16B	33.16	3,000	Positive News
ADPT Adaptive Biotechnologies	1.72 of 5 stars	$24.92 -1.1%	$24.42 -2.0%	+91.2%	$4.02B	$276.98M	N/A	790	Positive News Gap Down
ALMR Alamar Biosciences	1.9753 of 5 stars	$30.54 -0.6%	$31.80 +4.1%	N/A	$2.13B	$74.21M	N/A	222

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSNL) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Personalis (PSNL) Competitors

PSNL vs. STVN, SHC, ADPT, ALMR, and MRVI

How does Personalis compare to Stevanato Group?

Summary

How does Personalis compare to Sotera Health?

Summary

How does Personalis compare to Adaptive Biotechnologies?

Summary

How does Personalis compare to Alamar Biosciences?

Summary

How does Personalis compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Personalis (PSNL) Competitors

PSNL vs. STVN, SHC, ADPT, ALMR, and MRVI

How does Personalis compare to Stevanato Group?

Which has more volatility and risk, STVN or PSNL?

Is STVN or PSNL more profitable?

Does the media refer more to STVN or PSNL?

Which has better earnings and valuation, STVN or PSNL?

Do analysts prefer STVN or PSNL?

Do institutionals and insiders have more ownership in STVN or PSNL?

Summary

How does Personalis compare to Sotera Health?

Is SHC or PSNL more profitable?

Does the media refer more to SHC or PSNL?

Which has more risk & volatility, SHC or PSNL?

Do analysts recommend SHC or PSNL?

Which has preferable earnings & valuation, SHC or PSNL?

Do institutionals and insiders hold more shares of SHC or PSNL?

Summary

How does Personalis compare to Adaptive Biotechnologies?

Which has more risk & volatility, PSNL or ADPT?

Does the media prefer PSNL or ADPT?

Is PSNL or ADPT more profitable?

Do institutionals & insiders have more ownership in PSNL or ADPT?

Which has higher earnings and valuation, PSNL or ADPT?

Do analysts prefer PSNL or ADPT?

Summary

How does Personalis compare to Alamar Biosciences?

Which has higher valuation & earnings, ALMR or PSNL?

Do institutionals and insiders have more ownership in ALMR or PSNL?

Does the media prefer ALMR or PSNL?

Is ALMR or PSNL more profitable?

Do analysts recommend ALMR or PSNL?

Summary

How does Personalis compare to Maravai LifeSciences?

Which has stronger valuation & earnings, PSNL or MRVI?

Which has more risk and volatility, PSNL or MRVI?

Does the media prefer PSNL or MRVI?

Is PSNL or MRVI more profitable?

Do analysts recommend PSNL or MRVI?

Do institutionals & insiders believe in PSNL or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools